프로스타글란딘 제제에서 선택적 EP2 수용체 작용제로 변경 후 상안검 고랑 깊은 패임 회복
Recovery from Upper Eyelid Sulcus Deepening Following Switch from Prostaglandin Analogues to EP2 Receptor Agonist
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
목적: 프로스타글란딘 제제 사용 중 윗눈꺼풀 고랑의 깊은 패임이 나타난 녹내장 환자에서 EP2 수용체 작용제로 변경 후 윗눈꺼풀고랑 깊이가 회복된 1예를 보고하고자 한다. 증례요약: 65세 남자 환자가 녹내장 정밀검사를 위해 전원되었다. 초진 시 양안 최대교정시력 1.0, 안압 14/14 mmHg였다. 초기 노년성백내장 외 전안부 특이 소견은 없고 양안 중등도 녹내장 소견을 보여 bimatoprost/timolol fixed combination 제제를 처방하였다. 점안1개월 후 안압은 11/11 mmHg로, 10개월간 녹내장은 진행되지 않았다. 10개월째 안압은 17/18 mmHg로 다소 상승하였고, 환자는 양안상측 눈꺼풀 고랑의 깊은 패임을 호소하였다. 이에 따라, 기존 약제를 omidenepag isopropyl 점안액으로 교체하였다. 교체 2개월후 안압은 14/13 mmHg 유지 및 윗눈꺼풀 고랑 패임은 완전히 회복되었다. 결론: 프로스타글란딘 제제에 의한 윗눈꺼풀 고랑 패임과 같은 국소 부작용이 발생한 경우, 새로운 계열의 안압하강제인 EP2 수용체작용제로 교체해 볼 수 있다.
Abstract
Purpose: To report a case of recovery from deepening of the upper eyelid sulcus after switching from prostaglandin FP receptor agonists to an EP2 receptor agonist. Case summary: A 65-year-old male patient with suspicion of glaucoma presented for detailed examinations. At the initial visit, his best-corrected visual acuity was 1.0 in both eyes, and the intraocular pressure (IOP) was 14/14 mmHg. Examination revealed no specific findings in the anterior segment, mild early cataracts bilaterally, and moderate glaucomatous changes. Therefore, bimatoprost/timolol fixed-combination eye drops were administered in both eyes. After 1 month, the IOP was 11/11 mmHg and no evidence of glaucoma progression was found. After 10 months, the IOP was 17/18 mmHg and there was deepening of the upper eyelid sulcus bilaterally. Consequently, bimatoprost/timolol fixed combination eye drops were switched to omidenepag isopropyl. Within 2 months of the switch, the deepening of the upper eyelid sulcus recovered completely and the IOP was 14/13 mmHg. Conclusions: Patients with prostaglandin-associated periorbitopathy should be switched to non-prostaglandin drugs or EP2 receptor agonists. Our patient exhibited complete recovery of the upper eyelid sulcus deepening after switching to an EP2 agonist.
참고문헌 (15)
- Nakakura S, "Changes in prostaglandinassociated periorbital syndrome after switch from conventional prostaglandin F2α treatment to omidenepag isopropyl in 11 consecutive patients", J Glaucoma, 29, pp.326~328 (2020)
- Peplinski LS, "Deepening of lid sulcus from topical bimatoprost therapy", Optom Vis Sci, 81, pp.574~577 (2004)
- 이중원, "비마토프로스트 점안 후 발생한 깊은 위눈꺼풀고랑 2례", 대한안과학회지, 48(2), pp.332~336 (2007), 대한안과학회
- Kim HW, "Periorbital changes associated with prostaglandin analogs in Korean patients", BMC Ophthalmology, 17, pp.126~ (2017)
- Duggan S, "Omidenepag isopropyl ophthalmic solution 0.002%:first global approval", Drugs, 78, pp.1925~1929 (2018)
- Aihara M, "Phase 2, randomized, dose-finding studies of omidenepag isopropyl, a selective EP2 agonist, in patients with primary open-angle glaucoma or ocular hypertension", J Glaucoma, 28, pp.375~385 (2019)
- Sakata R, "Recovery of deepening of the upper eyelid sulcus after switching from prostaglandin FP receptor agonists to EP2 receptor agonist : a 3-month prospective analysis", Jpn J Ophthalmol, 65, pp.591~597 (2021)
- Taketani Y, "Activation of the prostanoid FP receptor inhibits adipogenesis leading to deepening of the upper eyelid sulcus in prostaglandin-associated periorbitopathy", Invest Ophthalmol Vis Sci, 55, pp.1269~1276 (2014)
- Alm A, "Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning:a comparison with timolol", Ophthalmology, 102, pp.1743~1752 (1995)
- Johnstone MA, "Prostaglandin-induced hair growth", Surv Ophthalmol, 47, pp.S185~202 (2002)
- Weston BC, "Migraine headache associated with latanoprost", Arch Ophthalmol, 119, pp.300~301 (2001)
- Park J, "Changes to upper eyelid orbital fat from use of topical bimatoprost, travoprost, and latanoprost", Jpn J Ophthalmol, 55, pp.22~27 (2011)
- Yamamoto Y, "Effects of omidenepag, a selective EP2 receptor agonist on adipocyte differentiation", Invest Ophthalmol Vis Sci, 60, pp.3781~ (2019)
- Esaki Y, "Effects of a selective EP2 receptor agonist, omidenepag isopropyl, on eyelash growth in mice", Invest Ophthalmol Vis Sci, 59, pp.2718~ (2018)
- Sakata R, "Prostaglandin-associated periorbitopathy syndrome(PAPS) : addressing an unmet clinical need", Semin Ophthalmol, 37, pp.447~454 (2021)